Literature DB >> 27129488

Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.

Sanyog Jain1, Venkata Appa Reddy2, Sumit Arora2, Kamlesh Patel2.   

Abstract

Candesartan cilexetil (CC), an ester prodrug of candesartan, is BCS class II drug with extremely low aqueous solubility limiting its oral bioavailability. The present research aimed to develop a nanocrystalline formulation of CC with improved saturation solubility in gastrointestinal fluids and thereby, exhibiting enhanced oral bioavailability. CC nanocrystals were prepared using a low energy antisolvent precipitation methodology. A combination of hydroxypropyl methylcellulose (HPMC) and Pluronic® F 127 (50:50 w/w) was found to be optimum for the preparation of CC nanocrystals. The particle size, polydispersity index (PDI), and zeta potential of optimized formulation was found to be 159 ± 8.1 nm, 0.177 ± 0.043, and -23.7 ± 1.02 mV, respectively. Optimized formulation was found to possess irregular, plate-like morphology as evaluated by scanning electron microscopy and crystalline as evaluated by differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD). A significant increase in saturation solubility and dissolution rate of the optimized nanosuspension was observed at all the tested pH conditions. Optimized CC nanocrystals exhibited a storage stability of more than 3 months when stored under cold and room temperature conditions. In vitro Caco-2 permeability further revealed that CC nanocrystals exhibited nearly 4-fold increase in permeation rate compared to the free CC. In vivo oral bioavailability studies of optimized CC nanocrystals in murine model revealed 3.8-fold increase in the oral bioavailability and twice the C max as compared with the free CC when administered orally. In conclusion, this study has established a crystalline nanosuspension formulation of CC with improved oral bioavailability in murine model. Graphical Abstract Antisolvent precipitation methodology for the preparation of Candesartan Cilexetil nanocrystals for enhanced solubility and oral bioavailability.

Entities:  

Keywords:  Antisolvent precipitation; Candesartan cilexetil; Nanocrystals; Oral bioavailability; Saturation solubility

Mesh:

Substances:

Year:  2016        PMID: 27129488     DOI: 10.1007/s13346-016-0297-8

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  42 in total

1.  Solubility enhancement of hydrophobic compounds by cosolvents: role of solute hydrophobicity on the solubilization effect.

Authors:  Yasuhiro Miyako; Nawel Khalef; Katsumi Matsuzaki; Rodolfo Pinal
Journal:  Int J Pharm       Date:  2010-04-02       Impact factor: 5.875

2.  Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery.

Authors:  Liping Zhou; Linhong Yang; Suzanne Tilton; Jianling Wang
Journal:  J Pharm Sci       Date:  2007-11       Impact factor: 3.534

Review 3.  Oral delivery of anticancer drugs: challenges and opportunities.

Authors:  Kaushik Thanki; Rahul P Gangwal; Abhay T Sangamwar; Sanyog Jain
Journal:  J Control Release       Date:  2013-05-03       Impact factor: 9.776

4.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

Authors:  P Artursson; J Karlsson
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

5.  Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.

Authors:  S M Shaikh; A M Avachat
Journal:  Curr Drug Deliv       Date:  2011-07       Impact factor: 2.565

Review 6.  Structure and design of polymeric surfactant-based drug delivery systems.

Authors:  V P Torchilin
Journal:  J Control Release       Date:  2001-06-15       Impact factor: 9.776

7.  Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents.

Authors:  Kohsaku Kawakami; Naohiko Oda; Kyoko Miyoshi; Takeshi Funaki; Yasuo Ida
Journal:  Eur J Pharm Sci       Date:  2006-01-06       Impact factor: 4.384

8.  Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir.

Authors:  Sanyog Jain; Jagadish M Sharma; Amit K Jain; Rahul R Mahajan
Journal:  Nanomedicine (Lond)       Date:  2013-01-25       Impact factor: 5.307

9.  Long-term stability of quercetin nanocrystals prepared by different methods.

Authors:  Mitali Kakran; Ranjita Shegokar; Nanda Gopal Sahoo; Sven Gohla; Lin Li; Rainer H Müller
Journal:  J Pharm Pharmacol       Date:  2012-04-17       Impact factor: 3.765

Review 10.  Nanocrystal technology, drug delivery and clinical applications.

Authors:  Jens-Uwe A H Junghanns; Rainer H Müller
Journal:  Int J Nanomedicine       Date:  2008
View more
  4 in total

1.  Preparation and in-vitro/in-vivo characterization of trans-resveratrol nanocrystals for oral administration.

Authors:  Sandeep K Singh; Vishal Makadia; Shweta Sharma; Mamunur Rashid; Sudhir Shahi; Prabhat R Mishra; Mohammed Wahajuddin; Jiaur R Gayen
Journal:  Drug Deliv Transl Res       Date:  2017-06       Impact factor: 4.617

Review 2.  Nanocrystals for Improving Oral Bioavailability of Drugs: Intestinal Transport Mechanisms and Influencing Factors.

Authors:  Zonghua Tian; Yaping Mai; Tingting Meng; Shijie Ma; Guojing Gou; Jianhong Yang
Journal:  AAPS PharmSciTech       Date:  2021-06-14       Impact factor: 3.246

3.  A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.

Authors:  Emilia Jakubowska; Bartłomiej Milanowski; Janina Lulek
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 5.923

4.  Formulation and Characterization of Carbopol-934 Based Kojic Acid-Loaded Smart Nanocrystals: A Solubility Enhancement Approach.

Authors:  Barkat Ali Khan; Maryam Waheed; Khaled M Hosny; Waleed Y Rizg; Samar S Murshid; Majed Alharbi; Muhammad Khalid Khan
Journal:  Polymers (Basel)       Date:  2022-04-06       Impact factor: 4.329

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.